业绩持续低迷，振东制药高管频繁变动

Group 1 - The company announced the resignation of Vice President and Secretary Wang Zheyu due to job reassignment, with Chairman Li Kun acting as the interim Secretary until a new appointment is made [3] - Marketing President Wang Rui has been appointed as the new President of the company [3] - The company has experienced significant management changes, including the resignation of several executives over the past year, such as the CFO Liu Yongsen and former President Yang Lianmin due to retirement [3] Group 2 - Financial data indicates that the company's performance has been declining for three consecutive years, with revenues of 3.729 billion yuan, 3.626 billion yuan, and 2.971 billion yuan from 2022 to 2024, respectively [4] - The company has reported cumulative losses of 1.42 billion yuan over three years, with a net profit loss of 20.36 million yuan in the first three quarters of the previous year, a 49.2% decrease year-on-year [4] - The decline in performance has been attributed to significant arbitration matters with Longdi Pharmaceutical, asset impairment from overdue trust products, and changes in industry policies and market conditions affecting product sales and prices [4] Group 3 - Longdi Pharmaceutical, previously a subsidiary, contributed nearly 20% of the company's revenue and over 70% of its net profit from 2016 to 2020, making it a core pillar of the business [5] - The relationship between the company and Longdi has deteriorated, raising uncertainties about future collaboration [5] - The major shareholder's pledge ratio has decreased, with the company announcing the release of 40.6 million shares from pledge, accounting for 13.43% of its holdings and 4.09% of the total share capital [5]